CAMZYOS®▼ (mavacamten) is the first and only licensed selective, allosteric and reversible cardiac myosin inhibitor for symptomatic NYHA class II and III obstructive HCM.1
CAMZYOS (mavacamten) is the only licensed non-invasive oral therapy that targets the underlying pathophysiology of obstructive HCM by reducing excess formation of myosin-actin cross bridging.1–3
CAMZYOS (mavacamten) modulates the number of myosin heads that can enter power-generating states, thus reducing the probability of force-producing systolic and residual diastolic cross-bridge formation.1
